Advertisement
Singapore markets closed
  • Straits Times Index

    3,332.80
    -10.55 (-0.32%)
     
  • Nikkei

    39,583.08
    +241.54 (+0.61%)
     
  • Hang Seng

    17,718.61
    +2.14 (+0.01%)
     
  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     
  • Bitcoin USD

    60,868.81
    +606.27 (+1.01%)
     
  • CMC Crypto 200

    1,266.46
    -17.37 (-1.35%)
     
  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     
  • Dow

    39,118.86
    -45.20 (-0.12%)
     
  • Nasdaq

    17,732.60
    -126.08 (-0.71%)
     
  • Gold

    2,336.90
    +0.30 (+0.01%)
     
  • Crude Oil

    81.46
    -0.28 (-0.34%)
     
  • 10-Yr Bond

    4.3430
    +0.0550 (+1.28%)
     
  • FTSE Bursa Malaysia

    1,590.09
    +5.15 (+0.32%)
     
  • Jakarta Composite Index

    7,063.58
    +95.63 (+1.37%)
     
  • PSE Index

    6,411.91
    +21.33 (+0.33%)
     

Cross Country Healthcare (NASDAQ:CCRN) Might Have The Makings Of A Multi-Bagger

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expanding base of capital employed. If you see this, it typically means it's a company with a great business model and plenty of profitable reinvestment opportunities. So on that note, Cross Country Healthcare (NASDAQ:CCRN) looks quite promising in regards to its trends of return on capital.

What Is Return On Capital Employed (ROCE)?

If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. Analysts use this formula to calculate it for Cross Country Healthcare:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.15 = US$80m ÷ (US$648m - US$128m) (Based on the trailing twelve months to March 2024).

ADVERTISEMENT

So, Cross Country Healthcare has an ROCE of 15%. In absolute terms, that's a satisfactory return, but compared to the Healthcare industry average of 11% it's much better.

See our latest analysis for Cross Country Healthcare

roce
roce

Above you can see how the current ROCE for Cross Country Healthcare compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering Cross Country Healthcare for free.

What Does the ROCE Trend For Cross Country Healthcare Tell Us?

The trends we've noticed at Cross Country Healthcare are quite reassuring. The data shows that returns on capital have increased substantially over the last five years to 15%. Basically the business is earning more per dollar of capital invested and in addition to that, 48% more capital is being employed now too. The increasing returns on a growing amount of capital is common amongst multi-baggers and that's why we're impressed.

In Conclusion...

In summary, it's great to see that Cross Country Healthcare can compound returns by consistently reinvesting capital at increasing rates of return, because these are some of the key ingredients of those highly sought after multi-baggers. Since the stock has returned a solid 50% to shareholders over the last five years, it's fair to say investors are beginning to recognize these changes. Therefore, we think it would be worth your time to check if these trends are going to continue.

Cross Country Healthcare does have some risks, we noticed 3 warning signs (and 1 which is a bit unpleasant) we think you should know about.

For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com